LARVOL presented a moderated discussion with top oncologists following ASCO's Annual Meeting 2021. In the video below, Dr. Kevin Knopf, Dr. Sandip Patel, and Dr. Balazs Halmos discussed the practice-changing impact of ASCO presentations in lung cancer.

On June 7, 2021, LARVOL hosted an Oncology Panel to discuss the top lung cancer clinical trial abstracts presented during the American Society of Clinical Oncology (ASCO) Annual Meeting 2021, held on June 4-8, 2021. Dr. Kevin Knopf from the University of California, San Francisco moderated the discussion between lung cancer KOLs Dr. Sandip Patel from the University of California, San Diego and Dr. Balazs Halmos from Albert Einstein College of Medicine.

The discussion covered:
ASCO abstract #8500 IMpower010: Primary results of a phase Ⅲglobal study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stageⅠB-ⅢA non-small cell lung cancer (NSCLC);

ASCO abstract #9013 Randomized phase Ⅲ trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm);

ASCO abstract #3008 BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+NSCLC and RET-mutant MTC: Phase 1 study results.